Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.67 |
| ▸ | CTSS | P25774 | 7/20 | 0.67 |
| ▸ | CTSK | P43235 | 6/20 | 0.67 |
| ▸ | CTSB | P07858 | 2/20 | 0.67 |
| ▸ | CTSL | P07711 | 1/20 | 0.67 |
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420859 | 1.00 | REN (0.67) | RENCTSSCTSKCTSBCTSL | |
| SCHEMBL7618822 | 1.00 | REN (0.67) | RENCTSSCTSKCTSBCTSL | |
| SCHEMBL22962389 | 0.95 | REN (0.75) | RENCTSSCTSKCTSBCTSL | |
| SCHEMBL27555716 | 0.95 | REN (0.75) | RENCTSSCTSKCTSBCTSL | |
| SCHEMBL11050511 | 0.95 | REN (0.75) | RENCTSSCTSKCTSBCTSL | |
| SCHEMBL24438783 | 0.93 | CTSS (0.69) | RENCTSSCTSKCTSBCTSL | |
| SCHEMBL8182259 | 0.93 | CTSS (0.69) | RENCTSSCTSKCTSBCTSL | |
| SCHEMBL13821431 | 0.93 | CTSS (0.69) | RENCTSSCTSKCTSBCTSL | |
| SCHEMBL29484078 | 0.91 | REN (0.68) | RENCTSSCTSKCTSBCTSL | |
| SCHEMBL7208458 | 0.90 | REN (0.67) | RENCTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | claimed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | claimed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | claimed |
| CN-114736197-B | Imidazolidinone derivatives and their use | 南京医工医药技术有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114736197-A | Imidazolidinone derivatives and their use | 南京医工医药技术有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3753966-B1 | AMPHIPHILIC BLOCK COPOLYMER, PREPARATION METHOD THEREOF AND NANOMICELLE DRUG-LOADING SYSTEM | SHANGHAI BEST LINK BIOSCIENCE LLC (CN) | 2022-05-25 | — | — | EP | disclosed |
| EP-3753966-A1 | AMPHIPHILIC BLOCK COPOLYMER, PREPARATION METHOD THEREOF AND NANOMICELLE DRUG-LOADING SYSTEM | Selection Bioscience LLC (CN) | 2020-12-23 | — | — | EP | disclosed |
| CN-110078658-A | - two picolinamide catalyst of thiocarbamide and its preparation method and application | 南宁师范大学 | 2019-08-02 | — | — | CN | disclosed |
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-08-10 | — | — | US | disclosed |
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| WO-2015021305-A1 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERISTY OF NEW YORK (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2005097765-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| CN-1671654-A | Gelling agent | APPLIED NANOSYSTEMS BV (NL) | 2005-09-21 | — | — | CN | disclosed |
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-6323315-B1 | FOR THERAPY OF CANCER | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| WO-2001018032-A2 | DOLASTATIN PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
| US-5780588-A | ANTICARCINOGENIC AGENT | ARIZONA BOARD OF REGENTS (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0612762-B1 | Elucidation and synthesis of selected pentapeptides | UNIV ARIZONA (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0612762-A1 | Elucidation and synthesis of selected pentapeptides | ARIZONA BOARD OF REGENTS (US) | 1994-08-31 | — | — | EP | disclosed |
| EP-0376040-A2 | N-phosphinyl di-and tripeptides as renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | REN 614/4885CTSS 867/4885CTSK 1886/4885 |
| US-20170226155-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | REN 482/4885CTSS 14/4885CTSK 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.